[1]
|
Filippi L, Chiaravalloti A, Schillaci O, et al. Theranostic approaches in nuclear medicine: current status and future prospects[J]. Expert Rev Med Devices, 2020, 17: 331-343. doi: 10.1080/17434440.2020.1741348 |
[2]
|
Jokar N, Assadi M, Yordanova A, et al. Bench-to-Bedside Theranostics in Nuclear Medicine[J]. Curr Pharm Des, 2020, 26: 3804-3811. doi: 10.2174/1381612826666200218104313 |
[3]
|
Solnes LB, Shokeen M, Pandit-Taskar N. Novel Agents and Future Perspectives on Theranostics[J]. Semin Radiat Oncol, 2021, 31: 83-92. doi: 10.1016/j.semradonc.2020.07.010 |
[4]
|
O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer[J]. Semin Radiat Oncol, 2021, 31: 71-82. doi: 10.1016/j.semradonc.2020.07.004 |
[5]
|
张锦明, 杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32: 178-185. doi: 10.7538/tws.2019.32.03.0178
Zhang JM, Du J. Preparation of Radiopharmaceuticals in China: Current Status and Prospects[J]. Tongweisu, 2019, 32: 178-185. doi: 10.7538/tws.2019.32.03.0178 |
[6]
|
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1588-1601. doi: 10.1007/s00259-017-3728-y |
[7]
|
Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427 |
[8]
|
Ali N, Sebastian C, Foley RR, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy[J]. Nucl Med Commun, 2006, 27: 165-169. doi: 10.1097/01.mnm.0000194397.20067.b6 |
[9]
|
Nagarajah J, Janssen M, Hetkamp P, et al. Iodine Symporter Targeting with 124I/131I Theranostics[J]. J Nucl Med, 2017, 58: 34S-38S. doi: 10.2967/jnumed.116.186866 |
[10]
|
Gulec SA, Kuker RA, Goryawala M, et al. 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis[J]. Thyroid, 2016, 26: 441-448. doi: 10.1089/thy.2015.0482 |
[11]
|
Furuta N, Kiyota H, Yoshigoe F, et al. Diagnosis of pheochromocytoma using[123I]-compared with[131I]-metaiodobenzylguanidine scintigraphy[J]. Int J Urol, 1999, 6: 119-124. doi: 10.1046/j.1442-2042.1999.06310.x |
[12]
|
Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma[J]. J Nucl Med, 2019, 60: 623-630. doi: 10.2967/jnumed.118.217463 |
[13]
|
Willegaignon J, Crema KP, Oliveira NC, et al. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures[J]. Clin Nucl Med, 2018, 43: 572-578. doi: 10.1097/RLU.0000000000002158 |
[14]
|
Weber M, Schmitz J, Maric I, et al. Diagnostic performance of 124I-m-iodobenzylguanidine PET/CT in patients with pheochromocytoma[J]. J Nucl Med, 2021. doi: 10.2967/jnumed.121.262797. |
[15]
|
支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37: 67-78. doi: 10.3760/cma.j.issn.0253-3766.2015.01.014
Zhi XY, Shi YK, Yu JM. Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J]. Zhonghua Zhongliu Zazhi, 2015, 37: 67-78. doi: 10.3760/cma.j.issn.0253-3766.2015.01.014 |
[16]
|
陈跃, 赵军, 吴湖炳, 等. 18F-NaF PET/CT骨显像操作指南[J]. 中华核医学与分子影像杂志, 2016, 36: 76-78. doi: 10.3760/cma.j.issn.2095-2848.2016.01.018
Chen Y, Zhao J, Wu HB, et al. Operation guide of 18F-NaF PET/CT bone imaging[J]. Zhonghua Heyixue Yu Fenzi Yingxiang Zazhi, 2016, 36: 76-78. doi: 10.3760/cma.j.issn.2095-2848.2016.01.018 |
[17]
|
Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 846-859. doi: 10.1007/s00259-018-3947-x |
[18]
|
Manafi-Farid R, Masoumi F, Divband G, et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain[J]. J Clin Med, 2020, 9: 2622. doi: 10.3390/jcm9082622 |
[19]
|
Sadremomtaz A, Masoumi M. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides[J]. J Med Imaging Radiat Sci, 2019, 50: 272-279. doi: 10.1016/j.jmir.2018.12.005 |
[20]
|
Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT[J]. AJR Am J Roentgenol, 2018, 211: 267-277. doi: 10.2214/AJR.18.19881 |
[21]
|
陈跃, 霍力, 兰晓莉, 等. 68Ga-DOTA-生长抑素受体PET/CT神经内分泌肿瘤显像操作指南[J]. 中国医学影像技术, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm
Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-DOTA-conjugated somatostatin receptor PET/CT imaging in neuroendocrine neoplasms[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm |
[22]
|
Zhang J, Song Q, Cai L, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2020, 146: 1533-1543. doi: 10.1007/s00432-020-03181-2 |
[23]
|
Farolfi A, Lima GM, Oyen W, et al. Molecular Imaging and Theranostics-A Multidisciplinary Approach[J]. Semin Nucl Med, 2019, 49: 247-254. doi: 10.1053/j.semnuclmed.2019.02.002 |
[24]
|
Hamed M, Basha M, Ahmed H, et al. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy[J]. Acad Radiol, 2019, 26: 450-460. doi: 10.1016/j.acra.2018.05.020 |
[25]
|
陈跃, 霍力, 兰晓莉, 等. 68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南[J]. 中国医学影像技术, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm
Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-PSMA PET/CT imaging in prostatic cancer[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm |
[26]
|
Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2019, 213: 275-285. doi: 10.2214/AJR.18.20845 |
[27]
|
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2536-2544. doi: 10.1007/s00259-019-04485-3 |
[28]
|
Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients[J]. Theranostics, 2020, 10: 9364-9377. doi: 10.7150/thno.48107 |
[29]
|
Goldsmith SJ. Targeted Radionuclide Therapy: A Historical and Personal Review[J]. Semin Nucl Med, 2020, 50: 87-97. doi: 10.1053/j.semnuclmed.2019.07.006 |
[30]
|
Jokar N, Velikyan I, Ahmadzadehfar H, et al. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology[J]. Clin Nucl Med, 2021, 46: e410-e420. doi: 10.1097/RLU.0000000000003678 |
[31]
|
Jadvar H. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies[J]. Cancer Biother Radiopharm, 2020, 35: 475-484. doi: 10.1089/cbr.2019.3340 |
[32]
|
Brito AE, Etchebehere E. Radium-223 as an Approved Modality for Treatment of Bone Metastases[J]. Semin Nucl Med, 2020, 50: 177-192. doi: 10.1053/j.semnuclmed.2019.11.005 |
[33]
|
Frantellizzi V, Cosma L, Brunotti G, et al. Targeted Alpha Therapy with Thorium-227[J]. Cancer Biother Radiopharm, 2020, 35: 437-445. doi: 10.1089/cbr.2019.3105 |
[34]
|
Anand A, Trägårdh E, Edenbrandt L, et al. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients[J]. J Nucl Med, 2020, 61: 671-675. doi: 10.2967/jnumed.119.231100 |